Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study

BJU International

Volumn 101, Issue 11, 2008, Pages 1356-1361

  Walz, Jochen ^a   Shariat, Shahrokh F ^b   Suardi, Nazareno ^a   Perrotte, Paul ^a   Lotan, Yair ^b   Palapattu, Ganesh S ^d   Gupta, Amit ^b   Bastian, Patrick J ^d   Rogers, Craig G ^d   Vazina, Amnon ^c   Amiel, Gilad E ^c   Sagalowsky, Arthur I ^b   Schoenberg, Mark ^d   Lerner, Seth P ^c   Karakiewicz, Pierre I ^a,e  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Adjuvant chemotherapy; Bladder cancer; Cancer specific survival; Case control study; Cystectomy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CYSTECTOMY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 43049117575     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07524.x     Document Type: Article

References (29)

1. Sternberg CN, Calabro F. Chemotherapy and management of bladder tumours. BJU Int 2000 85 : 599 610
2. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003 21 : 690 6
3. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001 19 : 666 75
4. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases. J Urol 1997 158 : 393 9
5. Pectasides D, Pectasides M, Nikolaou M. Adjuvant and neoadjuvant chemotherapy in muscle invasive bladder cancer: literature review. Eur Urol 2005 48 : 60 7
6. Lotan Y, Gupta A, Shariat SF et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005 23 : 6533 9
7. Goebell PJ, vom Dorp F, Rubben H. [Value of systemic chemotherapy in bladder cancer]. Urologe A 2006 45 : 586 93
8. Flechon A, Fizazi K, Gourgou-Bourgade S et al. Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers. Anticancer Drugs 2006 17 : 705 8
9. Ruggeri EM, Giannarelli D, Bria E et al. Adjuvant chemotherapy in muscle-invasive bladder carcinoma: a pooled analysis from phase III studies. Cancer 2006 106 : 783 8
10. Karakiewicz PI, Shariat SF, Palapattu GS et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006 176 : 1354 61
11. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003 349 : 859 66
12. Medical Research Council, Australian Bladder Cancer Study Group, National Cancer Institute of Canada et al. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999 354 : 533 40
13. Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001 19 : 4005 13
14. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991 145 : 459 64
15. Collaboration ABCAM-a. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005 48 : 189 99
16. Austin H, Flanders WD, Rothman KJ. Bias arising in case-control studies from selection of controls from overlapping groups. Int J Epidemiol 1989 18 : 713 6
17. Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn. Philadelphia : Lippincott, Williams & Wilkins, 1998
18. Grimes DA, Schulz KF. Compared to what? Finding controls for case-control studies. Lancet 2005 365 : 1429 33
19. Harada K, Sakai I, Kurahashi T et al. Clinicopathological features of recurrence after radical cystectomy for patients with transitional cell carcinoma of the bladder. Int Urol Nephrol 2006 38 : 49 55
20. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000 18 : 3068 77
21. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005 23 : 4602 8
22. Anonymous. Neoadjuvant cisplatin methotrexate, vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999 354 : 533 40
23. Vieweg J, Whitmore WF Jr, Herr HW et al. The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1994 73 : 3020 8
24. Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994 152 : 81 4
25. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996 155 : 495 9
26. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992 148 : 302 6
27. Bono AV, Benvenuti C, Reali L et al. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 1989 303 : 533 40
28. Lehmann J, Franzaring L, Thuroff J, Wellek S, Stockle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int 2006 97 : 42 7
29. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 2000 11 : 851 6